预约演示
更新于：2025-06-21
Melitracen Hydrochloride
盐酸美利曲辛
更新于：2025-06-21
概要
基本信息
结构/序列
分子式C21H26ClN |
InChIKeyRADLXCPDUXFGFF-UHFFFAOYSA-N |
CAS号10563-70-9 |
关联
3
项与 盐酸美利曲辛 相关的临床试验NCT03600974
A New System for Diagnosis and Treatment of Gastroesophageal Refulx Diseases : Based on Endoscopy, pH Parameter, Impedence Parameter, High Resolution Manometry and Psychology
ChiCTR1800015990
Interventional, randomized, single dose, open-label, crossover, bioequivalence study in healthy men and women to compare two pharmaceutical formulations of flupentixol/melitracen (Deanxit) – in fasted and fed conditions
ChiCTR-IPR-15006877
Clinical efficacy and Safety of Flupentixol and Melitracen Tablets in Treating Glous hystericus
100 项与 盐酸美利曲辛 相关的临床结果
登录后查看更多信息
100 项与 盐酸美利曲辛 相关的转化医学
登录后查看更多信息
100 项与 盐酸美利曲辛 相关的专利（医药）
登录后查看更多信息
375
项与 盐酸美利曲辛 相关的文献（医药）2025-03-01INTERNATIONAL PSYCHOGERIATRICS
Treatment indications for antidepressants prescribed in primary health care facilities in Beijing, China
Letter
作者: Shi, Luwen ; Nie, Xiaoyan ; Zhang, Xinyan
To examine the prevalence of treatment indications for antidepressants and assessed temporal trends in antidepressant prescribing for depression among adult patients in primary health care facilities (PHFs) in China. Descriptive study of antidepressant prescriptions written by primary care physicians. Setting participants: Patients aged 18 years and above in 67 PHFs in Dongcheng district in Beijing between 1 January 2014 and 31 December 2022. Deidentified information including patient demographics,antidepressants prescribed,and corresponding diagnoses were extracted from the prescribing system. The primary outcome was the treatment indications for all antidepressants prescribed between 2014 and 2022. Prescriptions were classified as on-label or off-label depending on whether the drug was approved for the indication by China's National Medical Products Administration by September 2022. A total of 42379 antidepressant prescriptions were identified between 2014 and 2022. Only 21.21 % of antidepressant prescriptions were indicated for depression. Anxiety disorders (31.43 %), insomnia (20.07 %), pain(19.12 %) and digestive system disorders (16.34 %) are also frequently prescribed antidepressants by physicians. For these indications, the most frequently prescribed antidepressant was flupentixol/melitracen and sertraline.For 36.32 % of all antidepressant prescriptions,physicians prescribed a drug for an off-label indication,especially insomnia and pain.Physicians also prescribed antidepressants for several indications that were off-label for all antidepressants, including digestive system disorders and migraine. This study found compound antidepressants are widely prescribed and used off-label indications.There is a need for more evidence to evaluate the clinical outcomes associated with off-label antidepressant indications for older adults to optimise prescribing decisions at PHFs.
2025-03-01Current urology
Effectiveness of simultaneous electroacupuncture stimulation on the tibial and ilioinguinal-iliohypogastric nerves in the treatment of refractory overactive bladder syndrome in women
Article
作者: Song, Xin ; Huang, Jin ; Li, Ziwei ; Ji, Xiang ; Fang, Weilin ; Si, Junwen ; Weng, Zhijun ; Lv, Jianwei ; Lv, Tingting
Abstract:
Objectives:
The aim of this study was to observe the clinical effectiveness of simultaneous electroacupuncture stimulation on the tibial nerve (TN) and ilioinguinal-iliohypogastric nerve (IIN/IHN) in the treatment of refractory overactive bladder (OAB) in women.
Materials and methods:
A prospective study was conducted involving 94 female patients with a diagnosis of OAB in the Urology Department of our hospital from September 2022 to October 2023. The patients were randomly divided into a TN-IIN/IHN group and a control group, each comprising 47 cases. All patients in both groups had received anticholinergic muscarinic receptor antagonists (tolterodine/solifenacin), β3 receptor agonists, flupentixol/melitracen, and other basic treatment regimens with poor results. The TN-IIN/IHN group received simultaneous electroacupuncture on the TN and IIN/IHN, whereas the control group received pelvic floor muscle biofeedback electrical stimulation. Both groups underwent treatment 3 times a week for a total of 4 weeks. Bladder symptoms (24-hour voiding diary), OAB Symptom Score, OAB-Quality of Life Questionnaire, and anxiety and depression scores were compared and analyzed before treatment, after treatment, and at a 3-month follow-up. Clinical efficacy was also assessed.
Results:
Both groups showed significant improvement in voiding frequency, nocturia, urgency, OAB Symptom Score, and average voiding volume after treatment and at follow-up (p < 0.01). The TN-IIN/IHN group showed significantly superior results compared with the control group (p < 0.01). Quality of life scores and anxiety and depression scores significantly decreased (p < 0.01), with the TN-IIN/IHN group scores significantly lower than those of the control group (p < 0.01). The treatment success rate in the TN-IIN/IHN group was 84.78%, whereas that in the control group was 28.89%, showing a statistically significant difference (p < 0.01). No significant adverse reactions occurred in either group during the treatment period.
Conclusions:
Simultaneous electroacupuncture on the TN and IIN/IHN is effective in treating refractory OAB in women and has good long-term efficacy. This therapy is safe, convenient, and free of significant adverse reactions, providing a new approach for the clinical treatment of refractory OAB in these patients. It significantly improves bladder symptoms and alleviates anxiety and depression, thereby markedly enhancing the patients' quality of life.
2025-01-01Clinical Laboratory
A Case of Pseudo Prolactin Elevation Caused by Medication
Article
作者: He, Li-Qin ; Sun, Hong-Gang ; Liu, Lan-Bing
BACKGROUND:
After the patient had a long course of disease and symptoms of bilateral breast milk secretion, the doctor first considered that the patient had breast cancer. After screening and excluding the breast, he found that the patient had high prolactin, and suspected that the patient had a pituitary tumor. After breast cancer and pituitary adenoma were excluded, the doctor suspected that there might be interference of macroprolactin. After PEG treatment, we also excluded the interference of macroprolactin. After repeated communication with doctors and patients, we found that the patient had gone to a psychiatric hospital for treatment and taken the antidepressant drug Deanxit (Flupentixol and Melitracen tablets).
METHODS:
Flupentixol acts by antagonizing hypothalamic prolactin releasing inhibitory factors, reducing dopamine release, leading to hyperprolactinemia.
RESULTS:
The patient's examination found that prolactin was 3,172.9 mIU/L (normal range 108.80 - 557.10 mIU/L), and after PEG treatment, it was 2,692.86 mIU/L. Patient stopped using Deanxit for one month, and prolactin levels were 302.8 mIU/L.
CONCLUSIONS:
Only effective communication between laboratory and clinical departments can make laboratory results more accurate and provide strong guarantees for clinical diagnosis and treatment.
100 项与 盐酸美利曲辛 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 抑郁症 | - | - | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用